JPS6119604B2 - - Google Patents
Info
- Publication number
- JPS6119604B2 JPS6119604B2 JP57147866A JP14786682A JPS6119604B2 JP S6119604 B2 JPS6119604 B2 JP S6119604B2 JP 57147866 A JP57147866 A JP 57147866A JP 14786682 A JP14786682 A JP 14786682A JP S6119604 B2 JPS6119604 B2 JP S6119604B2
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- gelatin
- parts
- weight
- glycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002775 capsule Substances 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 235000011187 glycerol Nutrition 0.000 claims description 18
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 11
- 239000007903 gelatin capsule Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 5
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 37
- 108010010803 Gelatin Proteins 0.000 description 25
- 229920000159 gelatin Polymers 0.000 description 25
- 239000008273 gelatin Substances 0.000 description 25
- 235000019322 gelatine Nutrition 0.000 description 25
- 235000011852 gelatine desserts Nutrition 0.000 description 25
- 239000004480 active ingredient Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000011049 filling Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000004080 punching Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- PURJGKXXWJKIQR-UHFFFAOYSA-N 4-[(4-hydroxynaphthalen-1-yl)diazenyl]benzenesulfonic acid Chemical compound C12=CC=CC=C2C(O)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 PURJGKXXWJKIQR-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 235000013980 iron oxide Nutrition 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 210000003748 coronary sinus Anatomy 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- -1 yellow iron oxide Chemical class 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ILRKKHJEINIICQ-UHFFFAOYSA-N azanium;6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl)oxy]-5-(6-carboxy-3,4,5-trihydroxyoxan-2-yl)oxy-3,4-dihydroxyoxane-2-carboxylate Chemical compound N.CC1(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C(O)=O)CC5C4=CC(=O)C3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O ILRKKHJEINIICQ-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- MCTRZKAKODSRLQ-UHFFFAOYSA-N dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 MCTRZKAKODSRLQ-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010655 horseradish oil Substances 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
æ¬çºæã¯å ç¿ç®¡æŽ»æ§ãæãã
ïŒcoronaryactiveïŒååç©ãããªãã¡ïŒâïŒ2â²âã
ããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«âïŒïŒïŒâãž
ã«ã«ãã¡ããã·âïŒïŒïŒâãžãããããªãžã³ãå«
æããå è¡ç®¡æ¡åŒµäœçšããã€ç¬éå£äžæŸåºæ§èäž
è»ã«ãã»ã«å€ã®è£œé æ¹æ³ã«é¢ããã çºäœã«äŒŒãŠããäžã€æè¬çå¿æ§çºäœã®åœ¢ã§ãã
èªäœèšåºçã«ç©¶æãããŠããå è¡ç®¡ã®è¡è¡ã®é害
ã¯ãç·æ¥ã®è¬å€åŠçœ®ãå¿ èŠãšããçäœã®å åã§ã
ãã ãã®ãããªçºäœãèµ·ãæéã¯äºæž¬ããããšãã§
ããªãã®ã§ãçå¿çãç ãã§ããæ£è ã¯ãçºäœã
èµ·ã€ãéèªåã§åŠçœ®ã§ããããã«è¬å€ãææããŠ
ããªããã°ãªããªãããããã®è¬å€ããã³è£œå€ã®
圢æ ã¯ãæ£è èªèº«ãè¿ éäžã€ç¢ºå®ã«åŠçœ®ããããš
ãã§ããããã«ããããçš®é¡ã®èŠæ±ã«åã€ããã®
ã§ãªããã°ãªããªããäŸãã°ã (A) ãããã®è¬å€ã®è£œå€ã®åœ¢æ ã¯ãçºäœäžã®æ£è
ã®éãããè¡åèœåã«ãããããããæ£è ã確
å®äžã€å®¹æã«æçšã§ãããã®ã§ãªããã°ãªããª
ãã (B) çå¿çã®æ²»çã«åœ¹ç«ã€ç©è³ªã¯ãäžè¬ã«æ£ç¢ºãª
æè¬ãå¿ èŠãšããé«æŽ»æ§è¬å€ã§ããã®ã§ããã®
補å€ã®åœ¢æ ã¯é©éã®æè¬éã確ä¿ãããã®ã«ãµ
ãããããã®ã§ãªããã°ãªããªãã (C) çå¿çã®çºäœã«ã¯éåžžèããããªãèŠçãã
ã³æ¥µåºŠã®äžå®æã䌎ããæ©æ¢°çã«ã¯ãçºäœäžã®
å¿èã®è¡è¡ãæžããšã極端ãªå Žåã«ã¯æ»ã«è³ã
ããšãããå¿çã«å¯Ÿããæ°žä¹ çãªæå·ãçãã
ããšããããåŸã€ãŠãçå¿çã®æ²»çã«äœ¿çšãã
ãè¬å€ã¯ãæçã®å¯èœãªæéå ïŒæ°å以å ïŒã«
å åã«å¹ããã®ã§ãªããã°ãªããªãã äžèš(A)ä¹è³(C)é ã«æ²ããå¿ èŠäºé ã¯ãéçµå£ç
ã«ã®ã¿æäžããããšã®ã§ãã泚å°æº¶æ¶²ãæãã¯ç¹
滎è¬ã®åœ¢æ ã§ã®ã¿çµå£æäžããããšã®ã§ãã溶液
ã«ãã€ãŠã¯éæããããšãã§ããªããæ £ããŠããª
ãæ£è ã«ãšã€ãŠãéçµå£çã«èªå·±æ³šå ¥ããããšã¯
å°é£ã§ãããããŠçå¿çã®çºäœäžã¯äžå¯èœã§ã
ããç¹æ»Žè¬ã®åœ¢æ ã§æçšããªããã°ãªããªãçµå£
æäžçšã®æº¶æ¶²ç¶ã®åæäžéã¯ãåå¿ã«å¯Ÿããèœå
ãéåžžã«å¶éãããŠããæ£è ã«ãšã€ãŠãå åæ£ç¢º
ã«æ±ºå®ããããšãã§ããªããéå°æäžã®å Žåã«ã¯
å±éºãããã ïŒïŒïŒâãžãããããªãžã³èªå°äœãå è¡ç®¡æ¡åŒµ
å€ãšããŠäœçšãããããŠäžèšã®ç æ°ã®åŠçœ®ã«äœ¿çš
åºæ¥ãããšã¯æ¢ã«ç¥ãããŠããããã®çŸ€ã«å±ãã
ååç©ã¯é£æº¶è§£æ§ã§äžã€æ¥µããŠå âæåæ§ã§ã
ãã ãããã®æŽ»æ§æåãé å€ãŸãã¯ç³è¡£äžžã«è£œå€ã
ããã®ïŒè±åœç¹èš±ç¬¬1173862å·æ现æžåç §ïŒã¯åž
åãéåžžã«é ããããäœãå¹ãç®ãã¯ãããªãã
åŸã€ãŠããããååç©ããã€ãŠããé«ã掻æ§ãå
åã«çºæ®ãããããšãã§ããªãã åŸã€ãŠãïŒïŒïŒâãžãããããªãžã³èªå°äœã®é¡
èãªå è¡ç®¡æ¡åŒµäœçšãå®éäžå åã«çºæ®ãããã
ãšãã§ãã圢æ ã§ïŒïŒïŒâãžãããããªãžã³èªå°
äœããæäŸããããšãåè¿«ããèŠæã§ããã èäžæäžãããè¬å€ã¯è¿ éã«åžåãããéåžžã«
å¹ãç®ãã¯ããããšããŸãå ¬ç¥ã§ããïŒäŸãã°ã
ããã°ãªã»ãªã³ïŒãSoilmanãT.â Manual of
PharmacologyâW.B.Saunders Co.ã
PhiladelphiaãPa.ã1957幎ã631é ãã åŸã€ãŠã1.4âãžãããããªãžã³èªå°äœãå«æ
ãäžã€ããããèäžæäžããå Žåã«ãåžåããã
ããã«ã€ãããã補å€ã®åœ¢æ ã¯æ²»çã¯æ²»çåŠäžå€§
ããªé²æ©ã§ããã ä»åãå°ãªããšãäžèšã®ïŒæåãããªãã¡ã (a) ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ã
ã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžã
ããããªãžã³ ïŒéééšã (b) ã¢ã«ãã¬ã³éšåã«ïŒåã¯ïŒåã®ççŽ ååãæ
ãäžã€å¹³åååéã200ä¹è³600ã®ããªã¢ã«ãã¬
ã³ã°ãªã³ãŒã« ïŒä¹è³50éééšã奜ãŸããã¯15
ä¹è³35éééšãåã³ (c) ã°ãªã»ãªã³ ã®ïŒæåããäžéæåå€ãæ·»å ããåã¯æ·»å ããŠ
ããªãå¬ã¿ãã ãå¯èœãªãŒã©ãã³ã«ãã»ã«æ®»å ã«
å°å ¥ããããšã«ãã補é ãããå è¡ç®¡æ¡åŒµäœçšã
ãã€ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®ã¿ããå
èš(A)ïŒ(B)åã³(C)ã®ïŒã€ã®èŠæ±ã«åã€ã補å€åœ¢æ ã§
ããããã®è£œå€åœ¢æ ã«ããã°ã該掻æ§æåãéåžž
ã«è¿ éã«åžåããäžã€è©²æŽ»æ§æåã®äœçšãéåžžã«
è¿ éã«çŸãããããšãèŠåºãããã äžèšã®ãç¬éå£äžæŸåºæ§è»ã«ãã»ã«å€ã
ïŒinstant oralârelease soft capsuleïŒãªãè¡šçŸ
ã¯ãç¹å®ã®ç§€éãããéã®æµåæ§è¬å€çµæç©ãå«
æããäžè¬ã«ãŒã©ãã³æ§ã®è»ã«ãã»ã«å€ãæå³
ããæ£è ããã®ã«ãã»ã«å€ãå¬ã¿ãã ããšããã
ã«ãã€ãŠãã®ã«ãã»ã«å€ã®å 容ç©ãæ£è ã®å£ã®äž
ã«æŸåºãããããããè¬å€ãæ£è ã®èº«äœã«çŽã¡ã«
åžåãããã å¬ã¿ãã ãå¯èœãªãŒã©ãã³ã«ãã»ã«æ®»ãžã®äžèš
åæåã®å å¡«ã¯åžžæ³ã«åŸã€ãŠè¡ãªãããšãã§ã
ããäŸãã°ãäžèšæŽ»æ§æå(a)ãããããã®é åºã§
ããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«(b)ããã³ã°ãªã»ãªã³(c)
ãšæ··åãããããŠå Žåã«ããä»ã®åžžçšã®èª¿åè£å©
å€ãæ·»å ãããã®æ··åç©ãå°ãªããšããŒã©ãã³ã
å«æããå¬ã¿ãã ãå¯èœãªã«ãã»ã«æ®»äžã«å å¡«ã
ãããšã«ããã€ããããã ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ãå«æããæ¬çºæã®ã«ãã»ã«å€ã¯æ¬¡ã®åŠ
ãå©ç¹ã瀺ãïŒæ¬ã«ãã»ã«å€ã¯å¿ èµçºäœã®éã§ã
æ£è ãèªåèªèº«ã§çŽã¡ã«æçšããããšãã§ããã
ããæ°å以å ã«å¹ãç®ãçŸãããããŸãã該ç¬é
å£äžæŸåºæ§ã«ãã»ã«å€äžã«å«ãŸããäžèšæŽ»æ§æå
ã®éã¯åºå®ãããŠããã®ã§ãæè¬ã«é¢ããŠäœãå±
éºããªããããããæäžã極ããŠç°¡åã§ããïŒæ
äžã¯èäžæäžã«ãã€ãŠè¡ãªãããåŸã€ãŠäŸãã°æ
åã«æŽ»æ§æåãå«æããç¹æ»Žè¬ã®æ¶²æ»Žã®æ°ããã
ããå¿ èŠæ§ããªãã掻æ§æåã¯éåžžã«å âæåæ§
ã§ããããããã®ãããªåŠæ¹ã¯ãã®å Žåã«ã¯å šã
äžå¯èœã§ããã ãã®å âæåæ§ã¯ããŒã©ãã³ã«ãã»ã«æ®»ã«ãçœ
è²åã¯æè²ã®äžéæåå€ããã³ããã«æãŸãã
ã¯ã該äžéæåå€ã«å ããŠã250ä¹è³460nmã®æ³¢
é·ã®å ãåžåããç¡æ¯æ§ææãå«æããããå Žå
ã«ãç¹ã«å¯ŸåŠããããšãã§ããã æ¬çºæã«åŸãã«ãã»ã«å€ã«å«ãŸãã掻æ§æå
ã¯ãå ¬ç¥ã®åŒ ã®ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ã§ããïŒè±åœç¹èš±æ现æžç¬¬1173862å·å
ç §ïŒã æ¬çºæã«åŸã€ãŠçšããããããªã¢ã«ãã¬ã³ã°ãª
ã³ãŒã«ããŸãåæ§ã«å ¬ç¥ã§ããããããã¯200ä¹
è³600ã®å¹³åååéãæããã300ä¹è³600ã®å¹³å
ååéãæããããªãšãã¬ã³ã°ãªã³ãŒã«ããã³ïŒ
ãŸãã¯ããªãããã¬ã³ã°ãªã³ãŒã«ãäŸãã°ããªã°
ãªã³ãŒã«ïŒHoechstïŒãã«ãããŒã«ïŒïŒLutrol
ïŒïŒïŒBASFïŒãããªãžãªãŒã«ïŒPolydiolsïŒ
ïŒHulsïŒãã«ãŒãã¯ãã¯ã¹ïŒCarbowaxïŒ
ïŒUnion CarbideïŒããçšããããšã奜ãŸãããäž
ã§ããªãšãã¬ã³ã°ãªã³ãŒã«ãç¹ã«å¥œé©ã§ããã æŽã«å¿ èŠã«å¿ããŠé åããã調åè£å©å€ãšããŠ
次ã®ãã®ã䜿çšããããšãã§ããïŒéŠå³å€ïŒè³éŠ
å€ïŒã粟油ã奜ãŸããã¯ã¯ã€ãæ²¹ãããããã
æ²¹ãã¢ããªã³æ²¹ãã«ã©ãŠãšã€ãŒæ²¹ãã¬ã¢ã³æ²¹ãŸã
ã¯ãŠãŒã«ãªæš¹èïŒçå³å€ãäŸãã°ãµãã«ãªã³ãŸã
ã¯ãµãã«ãªã³ãããªãŠã ïŒå¯æº¶æ§ãµãã«ãªã³ïŒïŒ
ã°ãªã·ã«ãªãžã³é žã¢ã³ã¢ããŠã å¡©ãçã æ¬çºæã«åŸãã«ãã»ã«å€ã®ç ç¶å 容ç©ã«ã¯ãŸã
å°éã®æ°Žãå«ãŸããããšãã§ããã æ¬çºæã§çšããããã«ãã»ã«æ®»ã¯ãåºæ¥ããç¶
æ ïŒreadyâtoâuse stateïŒã§54ä¹è³80ïŒ ã®ãŒã©
ãã³ã10ä¹è³36ïŒ ã®ã°ãªã»ãªã³ïŒãŸãã¯ãœã«ãã
ãŒã«ïŒããã³ïŒä¹è³15ïŒ ã®æ°Žãå«æãããããŠãŸ
ããå Žåã«ããã0.5ä¹è³ïŒïŒ ã®äžéæåå€äŸã
ã°äºé žåãã¿ã³ïŒé»è²é žåéãèµ€è²é žåéãè€è²
é žåéãé»è²é žåéã®åŠãé žåéïŒãŸãã¯çé žã«
ã«ã·ãŠã 奜ãŸããã¯äºé žåãã¿ã³ãå«æãããã
ãããäžéæåå€ã¯è©²ã«ãã»ã«æ®»äžã«ããããå
ç¬ã§ååšããããšãã§ããæãã¯ïŒçš®åã¯ãã以
äžçµåãããŠå«æãããããšãã§ããã ããã«ã該ã«ãã»ã«æ®»ã«ã¯å¿ èŠã«å¿ããŠ250ä¹
è³460nmã奜ãŸããã¯280ä¹è³420nmã®ç¯å²å ã®
æ³¢é·ã®å ãåžåããã補è¬åŠçã«èš±å®¹ãããææ
ãå«ãŸããããšãã§ããããã®ãããªææãšããŠ
äŸãã°é£åææãäŸãã°ã²ã«ããªã¬ã³ãžâåã¯
ã¿ãŒãã©ã³ãžã䜿çšããããšãã§ããã ããããŠãã«ãã»ã«æ®»çšã®ãŒã©ãã³çµæç©ã¯ã
äŸãã°ã40ä¹è³66ïŒ ã®çŽç²ãªãŒã©ãã³ãïŒä¹è³36
ïŒ ã®ã°ãªã»ãªã³ïŒãŸãã¯ãœã«ãããŒã«ïŒããã³22
ä¹è³34ïŒ ã®æ°Žãšæ··åãããããŠãã®æ··åç©ããã
æéèšæœ€ãããããšã«ãã€ãŠè£œé ããããããã
åŸãææã«ããããã®çµæç©ãæ°æ³¡ããªããªããŸ
ã§60âã§æº¶èãããããŠäžéæåå€ããã³å¿ èŠã«
ããææâã²ã«ããªã¬ã³ãžââïŒã«ã©ãŒã»ã€ã³
ããã¯ã¹No.15985ïŒäžŠã³ã«å Žåã«ããããã«é²è
å€ïŒäŸãã°ïœâã¢ããå®æ¯éŠé žããœã«ãã³é žãã
ã³ãžã«ã¢ã«ã³ãŒã«çïŒã該çµæç©äžã«å質ã«æ··ã
ãããšãã§ããã äžèšã®ã«ãã»ã«æ®»ã«å å¡«ããããã®èª¿åç©ã®èª¿
補ã¯ãïŒâïŒïŒâãããããšãã«ïŒâïŒïŒïŒâãžã¡
ãã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžã
ããããªãžã³ããå ãã«å ç±ãäžã€æ¹æããªã
ããããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«ããã³ã°ãªã»ãªã³
ã«æº¶è§£ãããããšã«ãã€ãŠè¡ãªãããããŒã©ãã³
ã«ãã»ã«æ®»ãžã®å å¡«ã¯å ¬ç¥ã®æ¹æ³ãäŸãã°ã·ãšãŒ
ã©ãŒïŒSCHERERïŒãã©ã€ããŒïŒLEINERïŒãããŒ
ãã³ïŒNORTONïŒãŸãã¯ã¢ã¯ã³ã²ã«
ïŒACCOGELïŒæ©ãçšããŠè¡ãªããããå å¡«åŸã
ã«ãã»ã«ã也ç¥ããã°çŽã¡ã«äœ¿çšã§ããã ã«ãã»ã«æ®»äžã«ååšãããã°ãªã»ãªã³ã¯ã«ãã»
ã«å€ã®æ¶²ç¶å 容ç©äžã«äžéšç§»è¡ããããšãããã
åŸã€ãŠã調補åŸã®ã«ãã»ã«å€ã®æ¶²ç¶å 容ç©äžã®ã°
ãªã»ãªã³ã®éã¯ïŒéééšãè¶ ããããšãããã æ¬çºæã®ç¬éå£äžæŸåºæ§ã«ãã»ã«å€ã¯ã奜ãŸã
ãã¯èäžåžåã®ããã«çšããããã æ·»ä»ã®ã°ã©ãã¯ãç¹ã«ãã©ã¬ã«ã³ãäžã®æ¬çºæ
ã®ã«ãã»ã«å€ã«å«ãŸãã掻æ§æåã®ãçµå£æäžãš
æ¯èŒããå Žåã«ããããèäžåžåã«ããéåžžã«è¿
éãªå¹ãç®ã®çºçŸã瀺ããã®ã§ããã 該ã°ã©ãã¯ã麻é ããããããŠå ç¶èæŽã«ã«ã
ãŒãã«ããã蟌ãã ç¬ã«çš®ã ã®æ¹æ³ã§æè¬ããé
ã®æŽ»æ§æåãïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒ
âãžã¡ãã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒ
âãžãããããªãžã³ã®äœçšã瀺ãããã®ã§ããã
ããªãã¡ãæ¬çºæã«åŸãäžèšæŽ»æ§æåïŒmgïŒKgã
該掻æ§æåïŒéééšãã°ãªã»ãªã³1.67éééšãã
ãªãšãã¬ã³ã°ãªã³ãŒã«400 29éééšããã³æ°Ž1.67
éééšãããªã液ç¶çµæç©ã®åœ¢æ ã§ç¬ïŒäœé20ã
25KgïŒã«èäžæäžããåŸã®å ç¶éèã®è¡æ¶²äžã®é ž
çŽ å§ã®äžæãã該掻æ§æåïŒmgïŒKgããã©ã¬ã«ã³
ãäžã§åŸ®çŽ°åãã圢æ ã§èã«æœçšããå Žåãšæ¯èŒ
ããŠèšé²ããã該ã°ã©ãã«ã¯åïŒåã®è©Šéšã®å¹³å
å€ã瀺ãã æ·»ä»ã®ã°ã©ãã«ãããæ²ç·ã¯èäžæäžã«åŸãè¿
éãªå¹ãç®ã®çºçŸãæ確ã«ç€ºããŠãããïŒååŸã«
ã»ãŒæ倧å€ã«éããããäžæ¹èãžã®æäžã®å Žåã«
ã¯æäžåŸé žçŽ å§ã¯60ååŸã«åãå€ã«éããã«éã
ãªãã åºäœã®èª¿åç©ãäŸãã°é å€ãç³è¡£äžžçãšããŠæŽ»
æ§æåãæäžãããšãæŽã«æãŸãããªãå€ã瀺
ãã 360nmæ³¢é·ã®å ã«æããæã®è©²æŽ»æ§æåã®ãšã¿
ããŒã«æº¶æ¶²ã®å ååŠå解ã®çµæå€åã¯äžèšè¡šã«ç€º
ãéãã§ããã
ïŒcoronaryactiveïŒååç©ãããªãã¡ïŒâïŒ2â²âã
ããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«âïŒïŒïŒâãž
ã«ã«ãã¡ããã·âïŒïŒïŒâãžãããããªãžã³ãå«
æããå è¡ç®¡æ¡åŒµäœçšããã€ç¬éå£äžæŸåºæ§èäž
è»ã«ãã»ã«å€ã®è£œé æ¹æ³ã«é¢ããã çºäœã«äŒŒãŠããäžã€æè¬çå¿æ§çºäœã®åœ¢ã§ãã
èªäœèšåºçã«ç©¶æãããŠããå è¡ç®¡ã®è¡è¡ã®é害
ã¯ãç·æ¥ã®è¬å€åŠçœ®ãå¿ èŠãšããçäœã®å åã§ã
ãã ãã®ãããªçºäœãèµ·ãæéã¯äºæž¬ããããšãã§
ããªãã®ã§ãçå¿çãç ãã§ããæ£è ã¯ãçºäœã
èµ·ã€ãéèªåã§åŠçœ®ã§ããããã«è¬å€ãææããŠ
ããªããã°ãªããªãããããã®è¬å€ããã³è£œå€ã®
圢æ ã¯ãæ£è èªèº«ãè¿ éäžã€ç¢ºå®ã«åŠçœ®ããããš
ãã§ããããã«ããããçš®é¡ã®èŠæ±ã«åã€ããã®
ã§ãªããã°ãªããªããäŸãã°ã (A) ãããã®è¬å€ã®è£œå€ã®åœ¢æ ã¯ãçºäœäžã®æ£è
ã®éãããè¡åèœåã«ãããããããæ£è ã確
å®äžã€å®¹æã«æçšã§ãããã®ã§ãªããã°ãªããª
ãã (B) çå¿çã®æ²»çã«åœ¹ç«ã€ç©è³ªã¯ãäžè¬ã«æ£ç¢ºãª
æè¬ãå¿ èŠãšããé«æŽ»æ§è¬å€ã§ããã®ã§ããã®
補å€ã®åœ¢æ ã¯é©éã®æè¬éã確ä¿ãããã®ã«ãµ
ãããããã®ã§ãªããã°ãªããªãã (C) çå¿çã®çºäœã«ã¯éåžžèããããªãèŠçãã
ã³æ¥µåºŠã®äžå®æã䌎ããæ©æ¢°çã«ã¯ãçºäœäžã®
å¿èã®è¡è¡ãæžããšã極端ãªå Žåã«ã¯æ»ã«è³ã
ããšãããå¿çã«å¯Ÿããæ°žä¹ çãªæå·ãçãã
ããšããããåŸã€ãŠãçå¿çã®æ²»çã«äœ¿çšãã
ãè¬å€ã¯ãæçã®å¯èœãªæéå ïŒæ°å以å ïŒã«
å åã«å¹ããã®ã§ãªããã°ãªããªãã äžèš(A)ä¹è³(C)é ã«æ²ããå¿ èŠäºé ã¯ãéçµå£ç
ã«ã®ã¿æäžããããšã®ã§ãã泚å°æº¶æ¶²ãæãã¯ç¹
滎è¬ã®åœ¢æ ã§ã®ã¿çµå£æäžããããšã®ã§ãã溶液
ã«ãã€ãŠã¯éæããããšãã§ããªããæ £ããŠããª
ãæ£è ã«ãšã€ãŠãéçµå£çã«èªå·±æ³šå ¥ããããšã¯
å°é£ã§ãããããŠçå¿çã®çºäœäžã¯äžå¯èœã§ã
ããç¹æ»Žè¬ã®åœ¢æ ã§æçšããªããã°ãªããªãçµå£
æäžçšã®æº¶æ¶²ç¶ã®åæäžéã¯ãåå¿ã«å¯Ÿããèœå
ãéåžžã«å¶éãããŠããæ£è ã«ãšã€ãŠãå åæ£ç¢º
ã«æ±ºå®ããããšãã§ããªããéå°æäžã®å Žåã«ã¯
å±éºãããã ïŒïŒïŒâãžãããããªãžã³èªå°äœãå è¡ç®¡æ¡åŒµ
å€ãšããŠäœçšãããããŠäžèšã®ç æ°ã®åŠçœ®ã«äœ¿çš
åºæ¥ãããšã¯æ¢ã«ç¥ãããŠããããã®çŸ€ã«å±ãã
ååç©ã¯é£æº¶è§£æ§ã§äžã€æ¥µããŠå âæåæ§ã§ã
ãã ãããã®æŽ»æ§æåãé å€ãŸãã¯ç³è¡£äžžã«è£œå€ã
ããã®ïŒè±åœç¹èš±ç¬¬1173862å·æ现æžåç §ïŒã¯åž
åãéåžžã«é ããããäœãå¹ãç®ãã¯ãããªãã
åŸã€ãŠããããååç©ããã€ãŠããé«ã掻æ§ãå
åã«çºæ®ãããããšãã§ããªãã åŸã€ãŠãïŒïŒïŒâãžãããããªãžã³èªå°äœã®é¡
èãªå è¡ç®¡æ¡åŒµäœçšãå®éäžå åã«çºæ®ãããã
ãšãã§ãã圢æ ã§ïŒïŒïŒâãžãããããªãžã³èªå°
äœããæäŸããããšãåè¿«ããèŠæã§ããã èäžæäžãããè¬å€ã¯è¿ éã«åžåãããéåžžã«
å¹ãç®ãã¯ããããšããŸãå ¬ç¥ã§ããïŒäŸãã°ã
ããã°ãªã»ãªã³ïŒãSoilmanãT.â Manual of
PharmacologyâW.B.Saunders Co.ã
PhiladelphiaãPa.ã1957幎ã631é ãã åŸã€ãŠã1.4âãžãããããªãžã³èªå°äœãå«æ
ãäžã€ããããèäžæäžããå Žåã«ãåžåããã
ããã«ã€ãããã補å€ã®åœ¢æ ã¯æ²»çã¯æ²»çåŠäžå€§
ããªé²æ©ã§ããã ä»åãå°ãªããšãäžèšã®ïŒæåãããªãã¡ã (a) ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ã
ã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžã
ããããªãžã³ ïŒéééšã (b) ã¢ã«ãã¬ã³éšåã«ïŒåã¯ïŒåã®ççŽ ååãæ
ãäžã€å¹³åååéã200ä¹è³600ã®ããªã¢ã«ãã¬
ã³ã°ãªã³ãŒã« ïŒä¹è³50éééšã奜ãŸããã¯15
ä¹è³35éééšãåã³ (c) ã°ãªã»ãªã³ ã®ïŒæåããäžéæåå€ãæ·»å ããåã¯æ·»å ããŠ
ããªãå¬ã¿ãã ãå¯èœãªãŒã©ãã³ã«ãã»ã«æ®»å ã«
å°å ¥ããããšã«ãã補é ãããå è¡ç®¡æ¡åŒµäœçšã
ãã€ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®ã¿ããå
èš(A)ïŒ(B)åã³(C)ã®ïŒã€ã®èŠæ±ã«åã€ã補å€åœ¢æ ã§
ããããã®è£œå€åœ¢æ ã«ããã°ã該掻æ§æåãéåžž
ã«è¿ éã«åžåããäžã€è©²æŽ»æ§æåã®äœçšãéåžžã«
è¿ éã«çŸãããããšãèŠåºãããã äžèšã®ãç¬éå£äžæŸåºæ§è»ã«ãã»ã«å€ã
ïŒinstant oralârelease soft capsuleïŒãªãè¡šçŸ
ã¯ãç¹å®ã®ç§€éãããéã®æµåæ§è¬å€çµæç©ãå«
æããäžè¬ã«ãŒã©ãã³æ§ã®è»ã«ãã»ã«å€ãæå³
ããæ£è ããã®ã«ãã»ã«å€ãå¬ã¿ãã ããšããã
ã«ãã€ãŠãã®ã«ãã»ã«å€ã®å 容ç©ãæ£è ã®å£ã®äž
ã«æŸåºãããããããè¬å€ãæ£è ã®èº«äœã«çŽã¡ã«
åžåãããã å¬ã¿ãã ãå¯èœãªãŒã©ãã³ã«ãã»ã«æ®»ãžã®äžèš
åæåã®å å¡«ã¯åžžæ³ã«åŸã€ãŠè¡ãªãããšãã§ã
ããäŸãã°ãäžèšæŽ»æ§æå(a)ãããããã®é åºã§
ããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«(b)ããã³ã°ãªã»ãªã³(c)
ãšæ··åãããããŠå Žåã«ããä»ã®åžžçšã®èª¿åè£å©
å€ãæ·»å ãããã®æ··åç©ãå°ãªããšããŒã©ãã³ã
å«æããå¬ã¿ãã ãå¯èœãªã«ãã»ã«æ®»äžã«å å¡«ã
ãããšã«ããã€ããããã ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ãå«æããæ¬çºæã®ã«ãã»ã«å€ã¯æ¬¡ã®åŠ
ãå©ç¹ã瀺ãïŒæ¬ã«ãã»ã«å€ã¯å¿ èµçºäœã®éã§ã
æ£è ãèªåèªèº«ã§çŽã¡ã«æçšããããšãã§ããã
ããæ°å以å ã«å¹ãç®ãçŸãããããŸãã該ç¬é
å£äžæŸåºæ§ã«ãã»ã«å€äžã«å«ãŸããäžèšæŽ»æ§æå
ã®éã¯åºå®ãããŠããã®ã§ãæè¬ã«é¢ããŠäœãå±
éºããªããããããæäžã極ããŠç°¡åã§ããïŒæ
äžã¯èäžæäžã«ãã€ãŠè¡ãªãããåŸã€ãŠäŸãã°æ
åã«æŽ»æ§æåãå«æããç¹æ»Žè¬ã®æ¶²æ»Žã®æ°ããã
ããå¿ èŠæ§ããªãã掻æ§æåã¯éåžžã«å âæåæ§
ã§ããããããã®ãããªåŠæ¹ã¯ãã®å Žåã«ã¯å šã
äžå¯èœã§ããã ãã®å âæåæ§ã¯ããŒã©ãã³ã«ãã»ã«æ®»ã«ãçœ
è²åã¯æè²ã®äžéæåå€ããã³ããã«æãŸãã
ã¯ã該äžéæåå€ã«å ããŠã250ä¹è³460nmã®æ³¢
é·ã®å ãåžåããç¡æ¯æ§ææãå«æããããå Žå
ã«ãç¹ã«å¯ŸåŠããããšãã§ããã æ¬çºæã«åŸãã«ãã»ã«å€ã«å«ãŸãã掻æ§æå
ã¯ãå ¬ç¥ã®åŒ ã®ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ã§ããïŒè±åœç¹èš±æ现æžç¬¬1173862å·å
ç §ïŒã æ¬çºæã«åŸã€ãŠçšããããããªã¢ã«ãã¬ã³ã°ãª
ã³ãŒã«ããŸãåæ§ã«å ¬ç¥ã§ããããããã¯200ä¹
è³600ã®å¹³åååéãæããã300ä¹è³600ã®å¹³å
ååéãæããããªãšãã¬ã³ã°ãªã³ãŒã«ããã³ïŒ
ãŸãã¯ããªãããã¬ã³ã°ãªã³ãŒã«ãäŸãã°ããªã°
ãªã³ãŒã«ïŒHoechstïŒãã«ãããŒã«ïŒïŒLutrol
ïŒïŒïŒBASFïŒãããªãžãªãŒã«ïŒPolydiolsïŒ
ïŒHulsïŒãã«ãŒãã¯ãã¯ã¹ïŒCarbowaxïŒ
ïŒUnion CarbideïŒããçšããããšã奜ãŸãããäž
ã§ããªãšãã¬ã³ã°ãªã³ãŒã«ãç¹ã«å¥œé©ã§ããã æŽã«å¿ èŠã«å¿ããŠé åããã調åè£å©å€ãšããŠ
次ã®ãã®ã䜿çšããããšãã§ããïŒéŠå³å€ïŒè³éŠ
å€ïŒã粟油ã奜ãŸããã¯ã¯ã€ãæ²¹ãããããã
æ²¹ãã¢ããªã³æ²¹ãã«ã©ãŠãšã€ãŒæ²¹ãã¬ã¢ã³æ²¹ãŸã
ã¯ãŠãŒã«ãªæš¹èïŒçå³å€ãäŸãã°ãµãã«ãªã³ãŸã
ã¯ãµãã«ãªã³ãããªãŠã ïŒå¯æº¶æ§ãµãã«ãªã³ïŒïŒ
ã°ãªã·ã«ãªãžã³é žã¢ã³ã¢ããŠã å¡©ãçã æ¬çºæã«åŸãã«ãã»ã«å€ã®ç ç¶å 容ç©ã«ã¯ãŸã
å°éã®æ°Žãå«ãŸããããšãã§ããã æ¬çºæã§çšããããã«ãã»ã«æ®»ã¯ãåºæ¥ããç¶
æ ïŒreadyâtoâuse stateïŒã§54ä¹è³80ïŒ ã®ãŒã©
ãã³ã10ä¹è³36ïŒ ã®ã°ãªã»ãªã³ïŒãŸãã¯ãœã«ãã
ãŒã«ïŒããã³ïŒä¹è³15ïŒ ã®æ°Žãå«æãããããŠãŸ
ããå Žåã«ããã0.5ä¹è³ïŒïŒ ã®äžéæåå€äŸã
ã°äºé žåãã¿ã³ïŒé»è²é žåéãèµ€è²é žåéãè€è²
é žåéãé»è²é žåéã®åŠãé žåéïŒãŸãã¯çé žã«
ã«ã·ãŠã 奜ãŸããã¯äºé žåãã¿ã³ãå«æãããã
ãããäžéæåå€ã¯è©²ã«ãã»ã«æ®»äžã«ããããå
ç¬ã§ååšããããšãã§ããæãã¯ïŒçš®åã¯ãã以
äžçµåãããŠå«æãããããšãã§ããã ããã«ã該ã«ãã»ã«æ®»ã«ã¯å¿ èŠã«å¿ããŠ250ä¹
è³460nmã奜ãŸããã¯280ä¹è³420nmã®ç¯å²å ã®
æ³¢é·ã®å ãåžåããã補è¬åŠçã«èš±å®¹ãããææ
ãå«ãŸããããšãã§ããããã®ãããªææãšããŠ
äŸãã°é£åææãäŸãã°ã²ã«ããªã¬ã³ãžâåã¯
ã¿ãŒãã©ã³ãžã䜿çšããããšãã§ããã ããããŠãã«ãã»ã«æ®»çšã®ãŒã©ãã³çµæç©ã¯ã
äŸãã°ã40ä¹è³66ïŒ ã®çŽç²ãªãŒã©ãã³ãïŒä¹è³36
ïŒ ã®ã°ãªã»ãªã³ïŒãŸãã¯ãœã«ãããŒã«ïŒããã³22
ä¹è³34ïŒ ã®æ°Žãšæ··åãããããŠãã®æ··åç©ããã
æéèšæœ€ãããããšã«ãã€ãŠè£œé ããããããã
åŸãææã«ããããã®çµæç©ãæ°æ³¡ããªããªããŸ
ã§60âã§æº¶èãããããŠäžéæåå€ããã³å¿ èŠã«
ããææâã²ã«ããªã¬ã³ãžââïŒã«ã©ãŒã»ã€ã³
ããã¯ã¹No.15985ïŒäžŠã³ã«å Žåã«ããããã«é²è
å€ïŒäŸãã°ïœâã¢ããå®æ¯éŠé žããœã«ãã³é žãã
ã³ãžã«ã¢ã«ã³ãŒã«çïŒã該çµæç©äžã«å質ã«æ··ã
ãããšãã§ããã äžèšã®ã«ãã»ã«æ®»ã«å å¡«ããããã®èª¿åç©ã®èª¿
補ã¯ãïŒâïŒïŒâãããããšãã«ïŒâïŒïŒïŒâãžã¡
ãã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžã
ããããªãžã³ããå ãã«å ç±ãäžã€æ¹æããªã
ããããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«ããã³ã°ãªã»ãªã³
ã«æº¶è§£ãããããšã«ãã€ãŠè¡ãªãããããŒã©ãã³
ã«ãã»ã«æ®»ãžã®å å¡«ã¯å ¬ç¥ã®æ¹æ³ãäŸãã°ã·ãšãŒ
ã©ãŒïŒSCHERERïŒãã©ã€ããŒïŒLEINERïŒãããŒ
ãã³ïŒNORTONïŒãŸãã¯ã¢ã¯ã³ã²ã«
ïŒACCOGELïŒæ©ãçšããŠè¡ãªããããå å¡«åŸã
ã«ãã»ã«ã也ç¥ããã°çŽã¡ã«äœ¿çšã§ããã ã«ãã»ã«æ®»äžã«ååšãããã°ãªã»ãªã³ã¯ã«ãã»
ã«å€ã®æ¶²ç¶å 容ç©äžã«äžéšç§»è¡ããããšãããã
åŸã€ãŠã調補åŸã®ã«ãã»ã«å€ã®æ¶²ç¶å 容ç©äžã®ã°
ãªã»ãªã³ã®éã¯ïŒéééšãè¶ ããããšãããã æ¬çºæã®ç¬éå£äžæŸåºæ§ã«ãã»ã«å€ã¯ã奜ãŸã
ãã¯èäžåžåã®ããã«çšããããã æ·»ä»ã®ã°ã©ãã¯ãç¹ã«ãã©ã¬ã«ã³ãäžã®æ¬çºæ
ã®ã«ãã»ã«å€ã«å«ãŸãã掻æ§æåã®ãçµå£æäžãš
æ¯èŒããå Žåã«ããããèäžåžåã«ããéåžžã«è¿
éãªå¹ãç®ã®çºçŸã瀺ããã®ã§ããã 該ã°ã©ãã¯ã麻é ããããããŠå ç¶èæŽã«ã«ã
ãŒãã«ããã蟌ãã ç¬ã«çš®ã ã®æ¹æ³ã§æè¬ããé
ã®æŽ»æ§æåãïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒ
âãžã¡ãã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒ
âãžãããããªãžã³ã®äœçšã瀺ãããã®ã§ããã
ããªãã¡ãæ¬çºæã«åŸãäžèšæŽ»æ§æåïŒmgïŒKgã
該掻æ§æåïŒéééšãã°ãªã»ãªã³1.67éééšãã
ãªãšãã¬ã³ã°ãªã³ãŒã«400 29éééšããã³æ°Ž1.67
éééšãããªã液ç¶çµæç©ã®åœ¢æ ã§ç¬ïŒäœé20ã
25KgïŒã«èäžæäžããåŸã®å ç¶éèã®è¡æ¶²äžã®é ž
çŽ å§ã®äžæãã該掻æ§æåïŒmgïŒKgããã©ã¬ã«ã³
ãäžã§åŸ®çŽ°åãã圢æ ã§èã«æœçšããå Žåãšæ¯èŒ
ããŠèšé²ããã該ã°ã©ãã«ã¯åïŒåã®è©Šéšã®å¹³å
å€ã瀺ãã æ·»ä»ã®ã°ã©ãã«ãããæ²ç·ã¯èäžæäžã«åŸãè¿
éãªå¹ãç®ã®çºçŸãæ確ã«ç€ºããŠãããïŒååŸã«
ã»ãŒæ倧å€ã«éããããäžæ¹èãžã®æäžã®å Žåã«
ã¯æäžåŸé žçŽ å§ã¯60ååŸã«åãå€ã«éããã«éã
ãªãã åºäœã®èª¿åç©ãäŸãã°é å€ãç³è¡£äžžçãšããŠæŽ»
æ§æåãæäžãããšãæŽã«æãŸãããªãå€ã瀺
ãã 360nmæ³¢é·ã®å ã«æããæã®è©²æŽ»æ§æåã®ãšã¿
ããŒã«æº¶æ¶²ã®å ååŠå解ã®çµæå€åã¯äžèšè¡šã«ç€º
ãéãã§ããã
ãè¡šã
次ã«æ¬çºæã®æ¹æ³ã«åŸãã«ãã»ã«å€ã«å
å¡«ãã
ããšã®ã§ãã液ç¶çµæç©ã®é åäŸã瀺ãã å®æœäŸ ïŒ ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ïŒä»¥äžããããšãžãã³ããšåŒã¶ïŒ30.0ïœ
ãã40âã«ãããŠæ¹æããªãããã°ãªã»ãªã³ïŒæ°Ž
ãå«ãŸãªãïŒ60.0ïœãæ°ŽïŒèžçãããã®ïŒ100.0
ïœåã³ããªãšãã¬ã³ã°ãªã³ãŒã«400 942.0ïœã®æ··
åç©äžã«æº¶è§£ããã次ãã§ãµãã«ãªã³ãããªãŠã
1.5ïœåã³ã¯ã€ãæ²¹2.5ïœãæ·»å ããããã®æ··åç©
ãç·å¯ã«æ··åãã次ãã§å®€æž©ã«ãããŠã«ãã»ã«æ®»
ã«å å¡«ããããšãã§ããã åã«ãã»ã«ã¯äžèšå å¡«ç©0.34mlãå«æããŠã
ããåŸã€ãŠãåæåã¯äžèšã®éééšã§ååšããïŒ ãããšãžãã³ ïŒéšïŒ30.0ïœïŒ ã°ãªã»ãªã³ ïŒéšïŒ60.0ïœïŒ æ°Ž 3.4éšïŒ100ïœïŒ ãµãã«ãªã³ãããªãŠã 0.05éšïŒ1.5ïœïŒ ã¯ã€ãæ²¹ 0.08éšïŒ2.5ïœïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«400 32éšïŒ942.0ïœïŒ äžèšå®æœäŸãšåæ§ã«ããŠãäžèšçµæã®ã«ãã»ã«
å å¡«ç©ã調補ããïŒ å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ ïŒéš æ°Ž ïŒéš ã¯ã€ãæ²¹ ïŒéš ããªãšãã¬ã³ã°ãªã³ãŒã«400 85éš å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ 20.3éš ããªãšãã¬ã³ã°ãªã³ãŒã«400 35.4éš å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ 10éš æ°Ž 10éš ããªãšãã¬ã³ã°ãªã³ãŒã«400 77éš ä»¥äžã®å®æœäŸã¯æ¬çºæã®ã«ãã»ã«å€ã«äœ¿çšãã
ãã«ãã»ã«æ®»ã®è£œé ã«é©ãããŒã©ãã³çµæç©ã®è£œ
é æ¹æ³ã説æãããã®ã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³46.0KgãããŒããŒäžã§æå
ã«ã°ãªã»ãªã³20.0Kgåã³æ¬¡ãã§æ°Ž34.0Kgã§æ¹¿ãã
ãããã®æ··åç©ãäžæ©æŸçœ®ãèšæœ€ããã次ãã§æ°Ž
ã§å ç±ãã容åšäžã§çŽ60âã«ãŠæ°æ³¡ãå«ãŸãªãã
ãã«ããŠæº¶èããããã®ãŒã©ãã³çµæç©ã¯ãŒã©ã
ã³ã«ãã»ã«æ®»ã®è£œé ã«äœ¿çšããããšãã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³ãã°ãªã»ãªã³24Kgåã³æ°Ž30
KgãšããŒããŒäžã§æ¹¿æœ€ãããããã®æ··åç©ãäžå€
èšæœ€ããã次ãã§æ°æ³¡ããšãããŸãªãããã«ããŠ
çŽ60âã«å ç±ãããåŸããããŒã©ãã³çµæç©ã¯ãŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã®ããã«äœ¿çšããããšã
ã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³46.0KgãããŒããŒäžã§æå
ã«ã°ãªã»ãªã³20.0Kgåã³æ¬¡ãã§34.0Kgã§åäžã«æ¹¿
ãããããã®æ··åç©ãäžæ©æŸçœ®ãèšæœ€ããã次ã
ã§æ°Žã§å ç±ãã容åšäžã§çŽ60âã§æº¶èãããã空
æ°æ³¡ããšãããŸãªãããã«æ¹æããªãããäºé žå
ãã¿ã³0.75Kgåã³âã²ã«ããªã¬ã³ãžââïŒã«ã©
ãŒã»ã€ã³ããã¯ã¹No.15ïŒ985ïŒ0.15Kgããã®ãŒã©
ãã³çµæç©ã«æ·»å ããããã®ãŒã©ãã³çµæç©ã¯ãŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã«äœ¿çšããããšãã§ã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³42.0Kgãé©åœãªãããµãŒäž
ã§ã°ãªã»ãªã³13.0Kgã§åäžã«æ¹¿ãããã次ãã§ãœ
ã«ãããŒã«15.0Kgåã³æ°Ž29.0Kgã®æº¶æ¶²ããã®æ··å
ç©ã«æ·»å ããåäžã«æ¹¿ããŸã§æ¹æããããã®æ··å
ç©ã12ä¹è³18æéèšæœ€ãããåŸãç空äžã§çŽ60ä¹
è³65âã§æ°æ³¡ãå«ãŸãªãããã«ããŠæº¶èããã ã¿ãŒãã©ãžã³ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.19ïŒ
140ïŒ0.1Kgãæ°Žäžã«æº¶è§£ãããããŠé»è²é žåé
ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.77ïŒ492ïŒ1.0Kgããã®
溶液ã«æ¹æããªããå ããã ãã®ç²ç ããææåã³é¡æã溶èããªããåäž
ã«æ··åããåŸããã®ãŒã©ãã³çµæç©ã¯ãŒã©ãã³ã«
ãã»ã«æ®»ã®è£œé ã®ããã«çŽãã«äœ¿çšã§ããã å®æœäŸ ïŒ ãŒã©ãã³é¡ç²41.0Kgããœã«ãããŒã«36.0Kgåã³
æ°Ž23.0Kgã®æº¶æ¶²ãšãåäžã«æ¹¿ããŸã§æ··ç·Žãããã
ãŠäžæ©èšæœ€ãããã次ãã§æ··åç©ã60ä¹è³65âã§
溶èãããçé žã«ã«ã·ãŠã 0.75Kgåã³èµ€è²é žåé
ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.77ïŒ491ïŒ0.75Kgãã
1.5Kgã®æ°Žäžã§äºãæ¹æããŠããŒã¹ããšãªãã
åŸããã®æº¶èç©äžã«å ãåäžã«ãªããŸã§åŠçã
ãããã®çµæç©ã¯ç©ºæ°æ³¡ããªããªããšããã«ããŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã®ããã«äœ¿çšããããšã
ã§ããã 次ã«ãæ¬çºæã®ç¬éå£äžæŸåºæ§è»ã«ãã»ã«å€ã
補é ããæ¹æ³ã®å ·äœäŸã瀺ãã å®æœäŸ 10 âãããã浞挬æ³ïŒ é©åœã«æ圢ãã浞挬åïŒãã³ïŒãçŽ60âã®æž©åºŠ
ãæãã空æ°æ³¡ãå«ãŸãªããŒã©ãã³çµæç©äžã«æµž
挬ããã 浞挬åãååºããšããŒã©ãã³çµæç©ããã³äžã§
åºåããŠãŽã ç¶ã®ç®ã圢æãããéå°ã®ãŒã©ãã³
çµæç©ã¯æ»Žäžããããã³ãã匟æ§ã®ã«ãã»ã«åã
åãã¯ããããããŠã«ãã»ã«æ®»ã®éŠãé©åœã«åæ
ããåŸãããããé©åœãªæ³šå°åšåã¯æ³šå ¥ãã³ãã«
ãã掻æ§æåãå«ãå å¡«ç©ã§å å¡«ãã次ãã§å£ã
ãŒã©ãã³çµæç©ã®å°æ»Žã§ã·ãŒã«ãããå å¡«ããã«
ãã»ã«ã¯ã埪ç°ç©ºæ°åŒãã©ã€ã€ãŒãŸãã¯ä¹Ÿç¥çšå
転çäžã§æ®ç湿åå«éãïŒä¹è³15ïŒ ã«ãªããŸã§ä¹Ÿ
ç¥ããåŸããã®ãŸãŸäœ¿çšããããšãã§ããããã®
æ¹æ³ã¯æåçããããã¯åãŸãã¯å®å šèªåçã«è¡
ãªãããšãã§ããã å®æœäŸ 11 âãã³ãã³ã°æ³ïŒPunching ProcessïŒïŒ ã·ãšãŒã©ãŒïŒSCHERERïŒåã³ã©ã€ããŒ
ïŒLEINERïŒæ³ã«ãããŠãçŽ60âã®æ¶²äœãŒã©ãã³
çµæç©ãïŒåã®ç©ºå·ããã·ãªã³ããŒäžã®ã¹ãã¬ã
ããŒã»ããã¯ã¹äžã«åäžã«æœçšããããŒã©ãã³çµ
æç©ãåºåãããŠïŒåã®ãŽã ç¶ã¹ããªããã圢æ
ãããã®ã¹ããªãããå察æ¹åã«å転ããŠããã
ãŒã¿ãªãŒã»ãã€ã«äŸçµŠãããããŒã¿ãªãŒã»ãã€é
ã§ããã±ããç¶æ§é ç©ãé£ç¶çã«åœ¢æãããåºéš
åã³äž¡åŽéšãæåã«æº¶æ¥ãããã掻æ§æåãå«ã
å å¡«ç©ããèšéãã³ãã«ããå å§äžã«å°å ¥ããå
å¡«ããã«ãã»ã«ã®é éšã溶æ¥ããããŠåãåºãã
埪ç°åŒç©ºæ°åŒãã©ã€ã€ãŒãŸãã¯ä¹Ÿç¥çšå転çäž
ã§ãæ®ç湿åå«éãïŒä¹è³15ïŒ ã«ãªããŸã§ä¹Ÿç¥ã
ãåŸãã«ãã»ã«å€ã¯çŽã¡ã«äœ¿çšããããšãã§ã
ãã å®æœäŸ 12 ããŒãã³ïŒNortonïŒæ³ã®åºç€ãšãªãåçã¯ã·
ãšãŒã©ãŒæ³ã®åçãšãã䌌ãŠãããããããªã
ããã«ãã»ã«ã®æåãå å¡«åã³ãã³ãã³ã°ã«ããŒ
ã¿ãªãŒã»ãã€ã䜿çšããããã®ä»£ãã«ïŒåã®æ¿ç¶
ã§ã¬ã³ãºïŒspecularïŒç¶ã®ãã³ãã³ã°åã䜿çšã
ãç¹ã§çžç°ããããããã®ãã³ãåã¯ããªãºãã«
ã«ã«çžäºã«å§æ¥ãããé¢ããããããåããªãºã
ã§ïŒåã®ãŒã©ãã³ã»ã¹ããªãããé éšããåºéšãž
ãžã€ãŒã¯ïŒjerkïŒã§åŒã€ã±ããããããŠãã«ãã»
ã«ãæ圢ããå å¡«ããããŠã·ãŒã«ããããŸãã¯ã
ã³ãã³ã°ããããããåŸã«ãã»ã«ãåžžæ³ã§ä¹Ÿç¥ã
ãã å®æœäŸ 13 ã¢ã¯ã³ã²ã«ïŒAccogelïŒæ³ããŸãããŒã¿ãªãŒã»
ãã€æ³ã§ãããããããªãããã·ãšãŒã©ãŒæ³ãšã¯
éã«ãã«ãã»ã«ã¯ç空äžã«è£œé ãããã äžæã®ãŒã©ãã³ã»ã¹ããªãããããŒã¿ãªãŒã»ã
ã€äžã«éããåã ã®åã«ç空ã«ãã€ãŠåžåŒããã
å å¡«ç©ãã«ãã»ã«æ®»ã®ååã«çžåœãããããã®ç©º
æŽã«å°å ¥ããã第äºã®ãŒã©ãã³ã»ã¹ããªãããæ¥
觊ããŒã©äžã移åãããå å¡«ããååã«å å§ã«ã
ã€ãŠé©çšããŠä»ã®ã«ãã»ã«æ®»ã®ååã®èã圢æã
ããããŠã«ãã»ã«ããã³ãã°ããã ã«ãã»ã«æ®»ã®ã·ãŒã«ã®åŸç空ãåãé€ããšçŽã¡
ã«ãäžã®ååã¯å°ãåçž®ããä»æ¹äžã®ååã¯å°ã
èšåŒµããããã®æ¹æ³ã§ããã³ãã³ã°ã®ç¶ç®ã«ãã€
ãŠæ®ãã©åãååãã€ã«åããããã«ãã»ã«ã圢
æããããã·ãšãŒã©ãŒåã³ããŒãã³æ³ã«ãããŠã
ãã³ãã³ã°ã®ç¶ç®ã¯ã«ãã»ã«æ®»ãæ£ç¢ºã«åãåå
ãã€ã«åããã也ç¥åŸãã«ãã»ã«ã¯ãã®ãŸãŸäœ¿çš
ã§ããã
ããšã®ã§ãã液ç¶çµæç©ã®é åäŸã瀺ãã å®æœäŸ ïŒ ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžããã
ããªãžã³ïŒä»¥äžããããšãžãã³ããšåŒã¶ïŒ30.0ïœ
ãã40âã«ãããŠæ¹æããªãããã°ãªã»ãªã³ïŒæ°Ž
ãå«ãŸãªãïŒ60.0ïœãæ°ŽïŒèžçãããã®ïŒ100.0
ïœåã³ããªãšãã¬ã³ã°ãªã³ãŒã«400 942.0ïœã®æ··
åç©äžã«æº¶è§£ããã次ãã§ãµãã«ãªã³ãããªãŠã
1.5ïœåã³ã¯ã€ãæ²¹2.5ïœãæ·»å ããããã®æ··åç©
ãç·å¯ã«æ··åãã次ãã§å®€æž©ã«ãããŠã«ãã»ã«æ®»
ã«å å¡«ããããšãã§ããã åã«ãã»ã«ã¯äžèšå å¡«ç©0.34mlãå«æããŠã
ããåŸã€ãŠãåæåã¯äžèšã®éééšã§ååšããïŒ ãããšãžãã³ ïŒéšïŒ30.0ïœïŒ ã°ãªã»ãªã³ ïŒéšïŒ60.0ïœïŒ æ°Ž 3.4éšïŒ100ïœïŒ ãµãã«ãªã³ãããªãŠã 0.05éšïŒ1.5ïœïŒ ã¯ã€ãæ²¹ 0.08éšïŒ2.5ïœïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«400 32éšïŒ942.0ïœïŒ äžèšå®æœäŸãšåæ§ã«ããŠãäžèšçµæã®ã«ãã»ã«
å å¡«ç©ã調補ããïŒ å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ ïŒéš æ°Ž ïŒéš ã¯ã€ãæ²¹ ïŒéš ããªãšãã¬ã³ã°ãªã³ãŒã«400 85éš å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ 20.3éš ããªãšãã¬ã³ã°ãªã³ãŒã«400 35.4éš å®æœäŸ ïŒ ãããšãžãã³ ïŒéš ã°ãªã»ãªã³ 10éš æ°Ž 10éš ããªãšãã¬ã³ã°ãªã³ãŒã«400 77éš ä»¥äžã®å®æœäŸã¯æ¬çºæã®ã«ãã»ã«å€ã«äœ¿çšãã
ãã«ãã»ã«æ®»ã®è£œé ã«é©ãããŒã©ãã³çµæç©ã®è£œ
é æ¹æ³ã説æãããã®ã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³46.0KgãããŒããŒäžã§æå
ã«ã°ãªã»ãªã³20.0Kgåã³æ¬¡ãã§æ°Ž34.0Kgã§æ¹¿ãã
ãããã®æ··åç©ãäžæ©æŸçœ®ãèšæœ€ããã次ãã§æ°Ž
ã§å ç±ãã容åšäžã§çŽ60âã«ãŠæ°æ³¡ãå«ãŸãªãã
ãã«ããŠæº¶èããããã®ãŒã©ãã³çµæç©ã¯ãŒã©ã
ã³ã«ãã»ã«æ®»ã®è£œé ã«äœ¿çšããããšãã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³ãã°ãªã»ãªã³24Kgåã³æ°Ž30
KgãšããŒããŒäžã§æ¹¿æœ€ãããããã®æ··åç©ãäžå€
èšæœ€ããã次ãã§æ°æ³¡ããšãããŸãªãããã«ããŠ
çŽ60âã«å ç±ãããåŸããããŒã©ãã³çµæç©ã¯ãŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã®ããã«äœ¿çšããããšã
ã§ããã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³46.0KgãããŒããŒäžã§æå
ã«ã°ãªã»ãªã³20.0Kgåã³æ¬¡ãã§34.0Kgã§åäžã«æ¹¿
ãããããã®æ··åç©ãäžæ©æŸçœ®ãèšæœ€ããã次ã
ã§æ°Žã§å ç±ãã容åšäžã§çŽ60âã§æº¶èãããã空
æ°æ³¡ããšãããŸãªãããã«æ¹æããªãããäºé žå
ãã¿ã³0.75Kgåã³âã²ã«ããªã¬ã³ãžââïŒã«ã©
ãŒã»ã€ã³ããã¯ã¹No.15ïŒ985ïŒ0.15Kgããã®ãŒã©
ãã³çµæç©ã«æ·»å ããããã®ãŒã©ãã³çµæç©ã¯ãŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã«äœ¿çšããããšãã§ã å®æœäŸ ïŒ é¡ç²åãããŒã©ãã³42.0Kgãé©åœãªãããµãŒäž
ã§ã°ãªã»ãªã³13.0Kgã§åäžã«æ¹¿ãããã次ãã§ãœ
ã«ãããŒã«15.0Kgåã³æ°Ž29.0Kgã®æº¶æ¶²ããã®æ··å
ç©ã«æ·»å ããåäžã«æ¹¿ããŸã§æ¹æããããã®æ··å
ç©ã12ä¹è³18æéèšæœ€ãããåŸãç空äžã§çŽ60ä¹
è³65âã§æ°æ³¡ãå«ãŸãªãããã«ããŠæº¶èããã ã¿ãŒãã©ãžã³ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.19ïŒ
140ïŒ0.1Kgãæ°Žäžã«æº¶è§£ãããããŠé»è²é žåé
ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.77ïŒ492ïŒ1.0Kgããã®
溶液ã«æ¹æããªããå ããã ãã®ç²ç ããææåã³é¡æã溶èããªããåäž
ã«æ··åããåŸããã®ãŒã©ãã³çµæç©ã¯ãŒã©ãã³ã«
ãã»ã«æ®»ã®è£œé ã®ããã«çŽãã«äœ¿çšã§ããã å®æœäŸ ïŒ ãŒã©ãã³é¡ç²41.0Kgããœã«ãããŒã«36.0Kgåã³
æ°Ž23.0Kgã®æº¶æ¶²ãšãåäžã«æ¹¿ããŸã§æ··ç·Žãããã
ãŠäžæ©èšæœ€ãããã次ãã§æ··åç©ã60ä¹è³65âã§
溶èãããçé žã«ã«ã·ãŠã 0.75Kgåã³èµ€è²é žåé
ïŒã«ã©ãŒã»ã€ã³ããã¯ã¹No.77ïŒ491ïŒ0.75Kgãã
1.5Kgã®æ°Žäžã§äºãæ¹æããŠããŒã¹ããšãªãã
åŸããã®æº¶èç©äžã«å ãåäžã«ãªããŸã§åŠçã
ãããã®çµæç©ã¯ç©ºæ°æ³¡ããªããªããšããã«ããŒ
ã©ãã³ã«ãã»ã«æ®»ã®è£œé ã®ããã«äœ¿çšããããšã
ã§ããã 次ã«ãæ¬çºæã®ç¬éå£äžæŸåºæ§è»ã«ãã»ã«å€ã
補é ããæ¹æ³ã®å ·äœäŸã瀺ãã å®æœäŸ 10 âãããã浞挬æ³ïŒ é©åœã«æ圢ãã浞挬åïŒãã³ïŒãçŽ60âã®æž©åºŠ
ãæãã空æ°æ³¡ãå«ãŸãªããŒã©ãã³çµæç©äžã«æµž
挬ããã 浞挬åãååºããšããŒã©ãã³çµæç©ããã³äžã§
åºåããŠãŽã ç¶ã®ç®ã圢æãããéå°ã®ãŒã©ãã³
çµæç©ã¯æ»Žäžããããã³ãã匟æ§ã®ã«ãã»ã«åã
åãã¯ããããããŠã«ãã»ã«æ®»ã®éŠãé©åœã«åæ
ããåŸãããããé©åœãªæ³šå°åšåã¯æ³šå ¥ãã³ãã«
ãã掻æ§æåãå«ãå å¡«ç©ã§å å¡«ãã次ãã§å£ã
ãŒã©ãã³çµæç©ã®å°æ»Žã§ã·ãŒã«ãããå å¡«ããã«
ãã»ã«ã¯ã埪ç°ç©ºæ°åŒãã©ã€ã€ãŒãŸãã¯ä¹Ÿç¥çšå
転çäžã§æ®ç湿åå«éãïŒä¹è³15ïŒ ã«ãªããŸã§ä¹Ÿ
ç¥ããåŸããã®ãŸãŸäœ¿çšããããšãã§ããããã®
æ¹æ³ã¯æåçããããã¯åãŸãã¯å®å šèªåçã«è¡
ãªãããšãã§ããã å®æœäŸ 11 âãã³ãã³ã°æ³ïŒPunching ProcessïŒïŒ ã·ãšãŒã©ãŒïŒSCHERERïŒåã³ã©ã€ããŒ
ïŒLEINERïŒæ³ã«ãããŠãçŽ60âã®æ¶²äœãŒã©ãã³
çµæç©ãïŒåã®ç©ºå·ããã·ãªã³ããŒäžã®ã¹ãã¬ã
ããŒã»ããã¯ã¹äžã«åäžã«æœçšããããŒã©ãã³çµ
æç©ãåºåãããŠïŒåã®ãŽã ç¶ã¹ããªããã圢æ
ãããã®ã¹ããªãããå察æ¹åã«å転ããŠããã
ãŒã¿ãªãŒã»ãã€ã«äŸçµŠãããããŒã¿ãªãŒã»ãã€é
ã§ããã±ããç¶æ§é ç©ãé£ç¶çã«åœ¢æãããåºéš
åã³äž¡åŽéšãæåã«æº¶æ¥ãããã掻æ§æåãå«ã
å å¡«ç©ããèšéãã³ãã«ããå å§äžã«å°å ¥ããå
å¡«ããã«ãã»ã«ã®é éšã溶æ¥ããããŠåãåºãã
埪ç°åŒç©ºæ°åŒãã©ã€ã€ãŒãŸãã¯ä¹Ÿç¥çšå転çäž
ã§ãæ®ç湿åå«éãïŒä¹è³15ïŒ ã«ãªããŸã§ä¹Ÿç¥ã
ãåŸãã«ãã»ã«å€ã¯çŽã¡ã«äœ¿çšããããšãã§ã
ãã å®æœäŸ 12 ããŒãã³ïŒNortonïŒæ³ã®åºç€ãšãªãåçã¯ã·
ãšãŒã©ãŒæ³ã®åçãšãã䌌ãŠãããããããªã
ããã«ãã»ã«ã®æåãå å¡«åã³ãã³ãã³ã°ã«ããŒ
ã¿ãªãŒã»ãã€ã䜿çšããããã®ä»£ãã«ïŒåã®æ¿ç¶
ã§ã¬ã³ãºïŒspecularïŒç¶ã®ãã³ãã³ã°åã䜿çšã
ãç¹ã§çžç°ããããããã®ãã³ãåã¯ããªãºãã«
ã«ã«çžäºã«å§æ¥ãããé¢ããããããåããªãºã
ã§ïŒåã®ãŒã©ãã³ã»ã¹ããªãããé éšããåºéšãž
ãžã€ãŒã¯ïŒjerkïŒã§åŒã€ã±ããããããŠãã«ãã»
ã«ãæ圢ããå å¡«ããããŠã·ãŒã«ããããŸãã¯ã
ã³ãã³ã°ããããããåŸã«ãã»ã«ãåžžæ³ã§ä¹Ÿç¥ã
ãã å®æœäŸ 13 ã¢ã¯ã³ã²ã«ïŒAccogelïŒæ³ããŸãããŒã¿ãªãŒã»
ãã€æ³ã§ãããããããªãããã·ãšãŒã©ãŒæ³ãšã¯
éã«ãã«ãã»ã«ã¯ç空äžã«è£œé ãããã äžæã®ãŒã©ãã³ã»ã¹ããªãããããŒã¿ãªãŒã»ã
ã€äžã«éããåã ã®åã«ç空ã«ãã€ãŠåžåŒããã
å å¡«ç©ãã«ãã»ã«æ®»ã®ååã«çžåœãããããã®ç©º
æŽã«å°å ¥ããã第äºã®ãŒã©ãã³ã»ã¹ããªãããæ¥
觊ããŒã©äžã移åãããå å¡«ããååã«å å§ã«ã
ã€ãŠé©çšããŠä»ã®ã«ãã»ã«æ®»ã®ååã®èã圢æã
ããããŠã«ãã»ã«ããã³ãã°ããã ã«ãã»ã«æ®»ã®ã·ãŒã«ã®åŸç空ãåãé€ããšçŽã¡
ã«ãäžã®ååã¯å°ãåçž®ããä»æ¹äžã®ååã¯å°ã
èšåŒµããããã®æ¹æ³ã§ããã³ãã³ã°ã®ç¶ç®ã«ãã€
ãŠæ®ãã©åãååãã€ã«åããããã«ãã»ã«ã圢
æããããã·ãšãŒã©ãŒåã³ããŒãã³æ³ã«ãããŠã
ãã³ãã³ã°ã®ç¶ç®ã¯ã«ãã»ã«æ®»ãæ£ç¢ºã«åãåå
ãã€ã«åããã也ç¥åŸãã«ãã»ã«ã¯ãã®ãŸãŸäœ¿çš
ã§ããã
æ·»ä»å³é¢ã¯ã麻é
ããããããŠå ç¶èæŽã«ã«ã
ãŒãã«ããã蟌ãã ç¬ã«å¯Ÿãããçš®ã ã®æäžåœ¢æ
ã®æŽ»æ§æåã®å¹ãç®ãæ¯èŒããã°ã©ãã§ããã
ãŒãã«ããã蟌ãã ç¬ã«å¯Ÿãããçš®ã ã®æäžåœ¢æ
ã®æŽ»æ§æåã®å¹ãç®ãæ¯èŒããã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ å°ãªããšãäžèšã®ïŒæåãããªãã¡ã (a) ïŒâïŒ2â²âãããããšãã«ïŒâïŒïŒïŒâãžã¡ã
ã«âïŒïŒïŒâãžã«ã«ãã¡ããã·âïŒïŒïŒâãžã
ããããªãžã³ ïŒéééšã (b) ã¢ã«ãã¬ã³éšåã«ïŒåã¯ïŒåã®ççŽ ååãæ
ãäžã€å¹³åååéã200ä¹è³600ã®ããªã¢ã«ãã¬
ã³ã°ãªã³ãŒã« ïŒä¹è³50éééšãåã³ (c) ã°ãªã»ãªã³ 0.5ä¹è³ïŒéééš ã®ïŒæåããäžéæåå€ãæ·»å ããåã¯æ·»å ããŠ
ããªãå¬ã¿ãã ãå¯èœãªãŒã©ãã³ã«ãã»ã«æ®»å ã«
å°å ¥ããããšãç¹åŸŽãšããå è¡ç®¡æ¡åŒµäœçšããã€
ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2142316 | 1971-08-24 | ||
DE2142316.5 | 1971-08-24 | ||
DE2209526.7 | 1972-02-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58121210A JPS58121210A (ja) | 1983-07-19 |
JPS6119604B2 true JPS6119604B2 (ja) | 1986-05-17 |
Family
ID=5817609
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14786782A Pending JPS58121211A (ja) | 1971-08-24 | 1982-08-27 | ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ |
JP14786682A Granted JPS58121210A (ja) | 1971-08-24 | 1982-08-27 | ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ |
JP14786882A Pending JPS58113126A (ja) | 1971-08-24 | 1982-08-27 | ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14786782A Pending JPS58121211A (ja) | 1971-08-24 | 1982-08-27 | ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14786882A Pending JPS58113126A (ja) | 1971-08-24 | 1982-08-27 | ç¬éå£äžæŸåºæ§èäžè»ã«ãã»ã«å€ã®è£œé æ¹æ³ |
Country Status (3)
Country | Link |
---|---|
JP (3) | JPS58121211A (ja) |
GT (1) | GT197749906A (ja) |
ZA (1) | ZA725808B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60105611A (ja) * | 1983-11-14 | 1985-06-11 | Nippon Chemiphar Co Ltd | ãããšãžãã³è»ã«ãã»ã«å€ |
JPS6397668A (ja) * | 1986-10-13 | 1988-04-28 | Lion Corp | èå æ§ã«ããã³ |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
JPS63238016A (ja) * | 1987-03-26 | 1988-10-04 | Tokai Kapuseru Kk | å¡©é žãã«ã«ãžãã³è»ã«ãã»ã«å€ |
AU2003231439A1 (en) * | 2002-05-09 | 2003-11-11 | Chugai Seiyaku Kabushiki Kaisha | Photostabilized soft capsule |
MX2015006022A (es) * | 2014-02-07 | 2015-10-14 | Scilabs Pharmaceuticals | Sistemas de administracion de farmacos sublinguales, totalmente naturales, no toxicos. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155587A (en) * | 1963-01-23 | 1964-11-03 | American Cyanamid Co | Stable liquid preparations of 7-chlorotetracycline |
GB1173862A (en) * | 1967-03-20 | 1969-12-10 | Bayer Ag | 4-Aryl-1,4-Dihydropyridine Derivatives and their production |
JPS4828621A (ja) * | 1971-08-24 | 1973-04-16 | ||
JPS5434048A (en) * | 1977-08-22 | 1979-03-13 | Nippon Electric Co | Method of making electrolytic capacitor |
JPS5637209A (en) * | 1979-09-05 | 1981-04-10 | Nissan Chem Ind Ltd | Continuous manufacture of phosphoric acid from unpulverized phosphate ore |
JPS6119604A (ja) * | 1984-07-05 | 1986-01-28 | Mitsubishi Electric Corp | 氎溶æ§å éåéå§å€ã®è£œæ³ |
-
1972
- 1972-08-23 ZA ZA725808A patent/ZA725808B/xx unknown
-
1977
- 1977-12-14 GT GT197749906A patent/GT197749906A/es unknown
-
1982
- 1982-08-27 JP JP14786782A patent/JPS58121211A/ja active Pending
- 1982-08-27 JP JP14786682A patent/JPS58121210A/ja active Granted
- 1982-08-27 JP JP14786882A patent/JPS58113126A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155587A (en) * | 1963-01-23 | 1964-11-03 | American Cyanamid Co | Stable liquid preparations of 7-chlorotetracycline |
GB1173862A (en) * | 1967-03-20 | 1969-12-10 | Bayer Ag | 4-Aryl-1,4-Dihydropyridine Derivatives and their production |
JPS4828621A (ja) * | 1971-08-24 | 1973-04-16 | ||
JPS5434048A (en) * | 1977-08-22 | 1979-03-13 | Nippon Electric Co | Method of making electrolytic capacitor |
JPS5637209A (en) * | 1979-09-05 | 1981-04-10 | Nissan Chem Ind Ltd | Continuous manufacture of phosphoric acid from unpulverized phosphate ore |
JPS6119604A (ja) * | 1984-07-05 | 1986-01-28 | Mitsubishi Electric Corp | 氎溶æ§å éåéå§å€ã®è£œæ³ |
Also Published As
Publication number | Publication date |
---|---|
GT197749906A (es) | 1979-06-07 |
JPS58121211A (ja) | 1983-07-19 |
ZA725808B (en) | 1973-05-30 |
JPS58121210A (ja) | 1983-07-19 |
JPS58113126A (ja) | 1983-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2135801C3 (de) | Weichgelatinekapseln | |
US3784684A (en) | Coronary dilator in a pharmaceutical dosage unit form | |
KR100634571B1 (ko) | ì°ì§ ì €ëŒíŽ ì ì ì© ìœí ì¡°ì±ë¬Œì ì ì¡° ë°©ë² | |
CZ345295A3 (en) | Soft gelatin pharmaceutical dosing form | |
HU198837B (en) | Process for producing hard gelatine capsule containing chewable composition | |
KR102663478B1 (ko) | ìë€ëŒë³ž ìœì íì ì¡°ì±ë¬Œ | |
JPS58194819A (ja) | èè žã§ã®è¬å€åžåãä¿é²ããè¬å€ãšããŠã®Î±âã±ãã¢ã«ããã | |
US2656298A (en) | Therapeutic product | |
DE2316242A1 (de) | Dosierform fuer aktive chemische verbindungen, insbesondere pharmazeutika, medikamente, nahrungsmittel und kosmetika, und verfahren zu ihrer herstellung | |
JPS58118510A (ja) | è¬ç©ã®çŽè žèŒžéçšè£å©è¬ | |
DE3400106A1 (de) | Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung | |
JPH0729916B2 (ja) | é®çæ§ãæããå»è¬çµæç© | |
JPS6119604B2 (ja) | ||
EP0205865B1 (de) | Pharmazeutische PrÀparate mit antihypertensiver und kardioprotektiver Wirkung | |
DK156121B (da) | Fremgangsmaade til fremstilling af et rectalt administrerbart suppositorium indeholdende et adjuvans | |
JP2665357B2 (ja) | å¿äžå šæ²»ççšå»è¬çµæç© | |
JPH06504539A (ja) | çµæç© | |
CS199202B2 (en) | Method of producing gelatine capsules to be bitten up | |
DE2903778A1 (de) | Verfahren zur thermischen stabilisierung und verbesserung der formbestaendigkeit von den pharmazeutischen wirkstoff in der huelle enthaltenden weichgelatine-kapseln | |
DE19912436A1 (de) | Ibuprofen-Lösung | |
JPH0132205B2 (ja) | ||
HU228857B1 (en) | Stable formulation containing fumagillin | |
US4098885A (en) | Equine anthelmintic | |
JPS6150915A (ja) | æã¢ã³ã®ãå»è¬çµæç© | |
US3140229A (en) | Laxative compositions containing (4, 4'-dihydroxy-2''-amino)-triphenylmethane and method of using same |